Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Rotterdam, Netherlands Clinical Trials

A listing of Rotterdam, Netherlands clinical trials actively recruiting patients volunteers.

RESULTS

Found (27) clinical trials

Phase I of SGM-101 in Patients With Cancer of the Colon Rectum or Pancreas

Surgery is the most important therapy for patients with cancer of the colon, rectum or pancreas. Complete resection, which is a crucial factor in the prognosis of a patient, is challenging as surgeons have to rely on visual appearance and palpation to discriminate between tumor and normal tissue. Carcinoembryonic antigen ...

Phase

0.0 miles

Learn More »

PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered intravenously (IV) as a single agent or in combination with ipilimumab or vemurafenib in adult subjects with advanced or recurrent solid tumors or lymphomas. PROCLAIM-CX-072: PRObody ...

Phase

0.0 miles

Learn More »

OMO-1 in Solid Malignancies

The study will consist of a number of study modules - the first of which is Module 1. Combination study modules will consist of a Part A (dose finding) and an optional Part B (cohort expansion). The option to start Part B and add further modules will be the decision ...

Phase

0.0 miles

Learn More »

An Open-Label Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

This is an open-label, dose-escalation/dose-expansion study of INCB059872 in subjects with advanced malignancies. The study will be conducted in 4 parts. Part 1 (mono therapy dose escalation) will determine the recommended dose(s) of INCB059872 for dose expansion, based on maximum tolerated dose and/or a tolerated pharmacologically active dose. Part 2 ...

Phase

0.0 miles

Learn More »

A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck

The addition of cetuximab to cisplatin and 5-FU in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) showed an improvement of overall survival (OS), progression free survival (PFS) and response rate (RR). However, cisplatin and 5-FU are toxic cytostatics for the vulnerable recurrent or metastatic SCCHN ...

Phase

0.0 miles

Learn More »

Pilot Study of FFP104 Dose Escalation in PBC Subjects

The purpose of this study is to determine the initial safety, tolerability and pharmacodynamics of the CD40-antagonist Mab, FFP104, in subjects with PBC

Phase

0.0 miles

Learn More »

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

The first molecular profiling protocols have been launched in Europe (MOSCATO-01 (Geoerger 2014), MAPPYACTS, INFORM, iTHER, SM-PAEDS, etc.) determining multiple actionable alterations in pediatric recurrent cancers. Increasingly, stratified approaches are being implemented to enrich clinical trials of molecularly targeted agents and possibly improve outcomes in specific populations i.e. a molecularly ...

Phase

0.0 miles

Learn More »

GEN3013 (DuoBody -CD3xCD20) Safety Trial in Patients With Relapsed Progressive or Refractory B-Cell Lymphoma

The trial is an open-label, multi-center safety trial of GEN3013 (DuoBody-CD3xCD20). The trial consists of two parts: a dose escalation part (phase 1, first-in-human (FIH) and an expansion part phase 2a). The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) has been determined.

Phase

0.0 miles

Learn More »

First-In-Human Study to Evaluate Safety Tolerability and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221

This is an open-label, fixed-sequence, ascending-dose, first-in-human study to evaluate the effect of a highly targeted rhGAA (ATB200) co-administered with a chaperone (AT2221). The study aims to evaluate safety, tolerability, pharmacodynamics (PD), and immunogenicity of ATB200 co-administered with AT2221. The study will be conducted in 3 stages. In Stage 1, ...

Phase

0.0 miles

Learn More »

S 81694 Plus Paclitaxel in Metastatic Breast Cancer

The purpose of this study is to determine the safety profile, the maximum tolerated dose (MTD) and the associated dose-limiting toxicities (DLTs) of S 81694 in combination with paclitaxel in metastatic breast cancer (mBC) patients, and to investigate the antitumour activity of the combination in metastatic triple negative breast cancer ...

Phase

0.51 miles

Learn More »